Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

ZF Lim, PC Ma - Journal of hematology & oncology, 2019 - Springer
The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges

E Sanz-Garcia, E Zhao, SV Bratman, LL Siu - Science Advances, 2022 - science.org
Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review

JD Merker, GR Oxnard, C Compton… - … of pathology & …, 2018 - meridian.allenpress.com
Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

Liquid biopsies: applications for cancer diagnosis and monitoring

I Martins, IP Ribeiro, J Jorge, AC Gonçalves… - Genes, 2021 - mdpi.com
The minimally—or non-invasive detection of circulating tumor-derived components in
biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential …

Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy

M Provencio, V Calvo, A Romero, JD Spicer… - American Society of …, 2022 - ascopubs.org
The treatment scenario for patients with resectable non–small cell lung cancer has changed
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …

Current status of circulating tumor cells, circulating tumor DNA, and exosomes in breast cancer liquid biopsies

M Tellez-Gabriel, E Knutsen, M Perander - International Journal of …, 2020 - mdpi.com
Breast cancer is the most common cancer among women worldwide. Although the five-, ten-
and fifteen-year survival rates are good for breast cancer patients diagnosed with early …

[HTML][HTML] Advances in lung cancer screening and early detection

C Li, H Wang, Y Jiang, W Fu, X Liu… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Lung cancer is associated with a heavy cancer-related burden in terms of patients' physical
and mental health worldwide. Two randomized controlled trials, the US-National Lung …

Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma

M Strijker, EC Soer, M de Pastena… - … journal of cancer, 2020 - Wiley Online Library
Circulating tumor DNA (ctDNA) is assumed to reflect tumor burden and has been suggested
as a tool for prognostication and follow‐up in patients with metastatic pancreatic ductal …

Current and developing liquid biopsy techniques for breast cancer

HJ Wu, PY Chu - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer is the most common cancer and leading cause of death
worldwide. Therefore, it is important to diagnose and treat breast cancer early. Current …

Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer

KCS Oliveira, IB Ramos, JMC Silva, WF Barra… - Molecular Cancer …, 2020 - AACR
Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive “liquid biopsy”
tool in precision medicine. ctDNA-genomic DNA fragments that are released into the …